glp-1 c elegans Mutation of GLP-1/Notch RAM domain results in a strong phenotype Lessons from C. elegans: signaling

G., Biftu, T., Chan, C

Not everyone needs the maximal efficacy of a triple agonist

Lilly is building a multi-engine growth machine: Alzheimer's Treatment Kisunla (Donanemab) - FDA-approved for early Alzheimer's, first proven to slow cognitive decline Represents a breakthrough in neurodegenerative disease treatment Oncology & Immunology Verzenio (breast cancer): $1.47B in Q3 2025 (+7% YoY) Jaypirca and Omvoh expanding in oncology and autoimmune markets Radiopharmaceutical investments through Point Biopharma ($1.4B acquisition) and Aktis Oncology partnership Pipeline Depth 40+ programs in Phase 2/3 across neuroscience, immunology, and cardiology Recent acquisitions: Scorpion Therapeutics, SiteOne Therapeutics, Adverum Biotechnologies Lilly isn't a one-trick pony

SGLT-2 inhibitors cause robust reduction of HHF and the renal outcome, and moderate reduction of CV or total deaths and MACE [13]

Healthcare professionals are encouraged to report any suspected counterfeit medications

All authors discussed the results and contributed to writing and editing the final manuscript